Detection of bla _KPC-2 in Proteus mirabilis in Brazil

Abstract

INTRODUCTION

: Infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing isolates pose a major worldwide public health problem today.

METHODS

: A carbapenem-resistant Proteus mirabilis clinical isolate was investigated for plasmid profiles and the occurrence of β-lactamase genes.

RESULTS

: The isolate exhibited resistance to ertapenem and imipenem and was susceptible to meropenem, polymyxin, and tigecycline. Five plasmids were identified in this isolate. DNA sequencing analysis revealed the presence of bla _KPC-2 and bla _TEM-1 genes. An additional PCR using plasmid DNA confirmed that bla _KPC-2 was present in one of these plasmids.

Conclusions:

We report the detection of bla _KPC-2 in P. mirabilis in Brazil for the first time. This finding highlights the continuous transfer of bla _KPC between bacterial genera, which presents a serious challenge to the prevention of infection by multidrug-resistant bacteria.

Proteus mirabilis; bla_KPC-2 ; Plasmid DNA

Klebsiella pneumoniae carbapenemase (KPC)-type enzymes were first reported in carbapenem-resistant K. pneumoniae strains in North Carolina, United States⁽¹⁾. Until 2005, the geographical distribution of these enzymes in members of the family Enterobacteriaceae - K. pneumoniae, in particular - was limited to the eastern part of the United States. In Brazil, KPC has been described since 2006, and it was first reported in K. pneumoniae isolates from Recife⁽²⁾, followed by reports⁽³⁾ in other species from the Enterobacteriaceae and non-fermenting bacilli^{(4) (5) (6)}. Carbapenem resistance in Proteus mirabilis caused by KPC-2 was also first reported in the United States⁽⁷⁾ in 2008, and currently, there are a few reports of P. mirabilis KPC producers worldwide^{(8) (9)}. The present report describes the detection of bla _KPC-2 in P. mirabilis strains in Brazil for the first time.

In May 2012, an isolate of Proteus mirabilis was recovered from the blood culture of a patient admitted to the intensive care unit of a tertiary hospital located in Recife, Pernambuco, Brazil. Biochemical identification and determination of minimum inhibitory concentrations (MICs) of the isolate were performed using the BD Phoenix^TM Automated Microbiology System, Franklin Lakes, New Jersey, USA and the susceptibility profile was determined according to the guidelines of the Clinical and Laboratory Standards Institute (2013). The isolate was characterized as multidrug resistant, showing resistance to amikacin (MIC>32µg/mL), amoxicillin/clavulanate (MIC>16µg/mL), ampicillin (MIC>16µg/mL), cefazolin (MIC>16µg/mL), cefepime (MIC>16µg/mL), cefotaxime (MIC>32µg/mL), cefoxitin (MIC=16µg/mL), ceftriaxone (MIC>32µg/mL), ciprofloxacin (MIC>2µg/mL), ertapenem (MIC>4µg/mL), imipenem (MIC>8µg/mL), gentamicin (MIC>8µg/mL), levofloxacin (MIC>4µg/mL), piperacillin/tazobactam (MIC>64µg/mL), and tobramycin (MIC>8µg/mL). It was susceptible only to meropenem, polymyxin, and tigecycline. Plasmid DNA was extracted by the UltraClean Endotoxin-Free Mini Plasmid Prep Kit (Mo Bio Lab, Carlsbad, CA, USA) and was visualized and analyzed by electrophoresis on a 0.7% agarose gel. The molecular weight of each plasmid was determined by comparison with plasmids of known molecular weight, e.g., with that of K. pneumoniae K16-P strain⁽³⁾. Five plasmids with estimated molecular sizes of >150kb, 150kb, 120kb, 90kb, and 70kb were identified in the isolate. Genes bla _KPC, bla _VIM, bla _IMP, bla _SPM, bla _GES, bla _SHV, bla _TEM, and bla _CTX-M were analyzed by PCR using genomic DNA and specific primers⁽³⁾. bla _VIM, bla _IMP, bla _SPM, bla _GES, bla _CTM-M, and bla _SHV were not present, while bla _KPC and bla _TEM were detected, amplifying fragments of approximately 1,000bp . An additional PCR using plasmid DNA for bla _KPC detection was performed to confirm the plasmid origin of this gene. The coding regions of bla _KPC and bla _TEM were sequenced, and the analysis of the nucleotide sequences and deduced protein sequences with BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and EXPASY (http://www.expasy.org translate) showed that the isolate harbored bla _KPC-2 and bla _TEM-1 (GenBank accession numbers KC736925 and KF811201). bla _TEM has been described in P. mirabilis from Brazil by Dropa et al. ⁽¹⁰⁾ and Abreu et al. ⁽¹¹⁾, but they did not sequence the gene. The analysis of antimicrobial agents revealed susceptibility to meropenem, polymyxin, and tigecycline. Tibbetts et al. ⁽⁷⁾ identified KPC-producing Proteus mirabilis isolates that were susceptible only to piperacillin/tazobactam and ciprofloxacin in USA, and Sheng et al. ⁽⁸⁾ identified a panresistant KPC-producing P. mirabilis isolate in China. According to Castanheira et al. ⁽¹²⁾, meropenem, ceftazidime-avibactam, and tigecycline were the most active antimicrobials against the KPC-producing Escherichia coli, K. pneumoniae, Klebsiella oxytoca, and P. mirabilis isolates collected in 2012 from the all United States Census Bureau-designated regions. The identification of bla _KPC-2 as the underlying basis of carbapenem resistance in P. mirabilis isolates is worrisome, although this finding is not totally unexpected, given the recent documented spread of bla _KPC carbapenemase to a number of gram-negative bacteria^{(4) (5) (13) (14)}, including in K. pneumoniae and Pseudomonas aeruginosa in the same hospital in Recife, Brazil^{(3) (6)}. These data indicate the intra-bacterial transference of bla _KPC-2 at this hospital. According to the literature, bla _KPC is encoded by transposon Tn4401, found in a variety of transferable plasmids^{(2) (15)}. In this study, PCR experiments using plasmid DNA confirmed that bla _KPC-2 was present in the plasmids. Considering that transposons are mobile genetic elements, bla _KPC-2 could be present in any of the 5 plasmids detected (>150 kb, 150kb, 120kb, 90kb, and 70kb). The data presented herein confirm that P. mirabilis strains harboring bla _KPC-2 are emerging in Brazil, suggesting the continuous transfer of bla _KPC between bacterial genera. This poses a serious challenge to prevent infections caused by multidrug-resistant bacteria.

• ¹
  Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD. Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45:1151-1161.
• ²
  Monteiro J, Santos AF, Asensi MD, Peirano G, Gales AC. First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. Antimicrob Agents Chemother2009; 53333-53334.
• ³
  Cabral AB, Melo RCA, Maciel MAV, Lopes ACS. Multidrug resistance genes, including blaKPC and blaCTX-M-2, among Klebsiella pneumoniae isolated in Recife, Brazil. Rev Soc Bras Med Trop 2012; 45:572-578.
• ⁴
  Almeida ACS, Cavalcanti FLS, Vilela MA, Gales AC, de Morais Junior MA, de Morais MMC. Escherichia coli ST502 and Klebsiella pneumoniae ST11 sharing an IncW plasmid harbouring the blaKPC-2 gene in an Intensive Care Unit patient. Int J Antimicrob Agents 2012; 40: 374-376.
• ⁵
  Almeida ACS, Vilela MA, Cavalcanti FLS, Martin WMBS, Morais Junior MA, Morais MMC. First description of KPC-2-producing Pseudomonas putida in Brazil. Antimicrob Agents Chemother2012; 56:2205-2206.
• ⁶
  Jácome PRLA, Alves LR, Cabral AB, Lopes ACS,. Maciel MAV First Report of KPC-Producing Pseudomonas aeruginosa in Brazil. Antimicrob Agents Chemother2012; 56:4990.
• ⁷
  Tibbetts R, Frye JG, Marschall J, Warren D, Dunne W. Detection of KPC-2 in a Clinical Isolate of Proteus mirabilis and First Reported Description of Carbapenemase Resistance Caused by a KPC β-Lactamase in P. mirabilis. J Clin Microbiol 2008; 46:3080-3083.
• ⁸
  Sheng Z, Li J, Sheng G, Sheng J, Li L. Emergence of Klebsiella pneumonia carbapenemase-producing Proteus mirabilis in Hangzhou, China. Chin Med J2010; 123:2568-2570.
• ⁹
  Hu YY, Cai JC, Zhang R, Zhou HW, Sun Q, Chen GX. Emergence of Proteus mirabilis harboring blaKPC-2 and qnrD in a Chinese Hospital. Antimicrob Agents Chemother2012; 56:2278-2282.
• ¹⁰
  Dropa M, Balsalobre LC, Lincopan N, Mamizuka EM, Murakami T, Cassettari VC. Extended-spectrum beta-lactamases among Enterobacteriaceae isolated in a public hospital in Brazil. Rev Inst Med Trop São Paulo 2009; 51:203-209.
• ¹¹
  Abreu AG, Marques SG, Monteiro-Neto V, de Carvalho RML, Gonçalves AG. Nosocomial infection and characterization of extended-spectrum β-lactamases-producing Enterobacteriaceae in northeast Brazil. Rev Soc Bras Med Trop2011; 44:441-446.
• ¹²
  Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother2014; 58:833-838.
• ¹³
  D'Alincourt Carvalho-Assef AP, Leão RS, da Silva RV, Ferreira AG, Seki LM,. Asensi MD Escherichia coli producing KPC-2 carbapenemase: first report in Brazil. Diagn Microbiol Infect Dis 2010; 68:337-338.
• ¹⁴
  Andrade LN, Curião T, Ferreira JC, Longo JM, Clímaco EC, Martinez R. Dissemination of blaKPC-2 by the Spread of Klebsiella pneumoniae Clonal Complex 258 Clones (ST258, ST11, ST437) and Plasmids (IncFII, IncN, IncL/M) among Enterobacteriaceae Species in Brazil. Antimicrob Agents Chemother2011; 55: 3579-3583.
• ¹⁵
  Patel JB, Rasheed JK, Kitchel B. Carbapenemases in Enterobacteriaceae: Activity, Epidemiology, and Laboratory Detection. Clin Microbiol Newsletter2009; 31:55-62.

Publication Dates

• Publication in this collection
  Feb 2015

History

• Received
  04 July 2014
• Accepted
  05 Nov 2014